China
Every company in the roster headquartered in China.
Every company in the roster headquartered in China.
130 of 130 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
| 5 assets: 3 Ph 3, 1 Ph 2, 1 Ph 1 | LisaftoclaxPhase 3 · Acute Myeloid LeukemiaWeak signal | Dec 2026Lisaftoclax · Phase 2 | — | $122MDec 2024 | ~31.6 qtrs | $132M | |
Ascletis Pharma1672 · HKEX | 4 assets: 3 Ph 3, 1 Ph 1 | DenifanstatPhase 3 · Recurrent GlioblastomaReliable signal | Dec 2026Envafolimab · Phase 2 | — | $206MDec 2025 | ~4.1 qtrs | $57M |
Asieris Pharmaceuticals688176 · SSE STAR Market | 1 asset: 1 Ph 1 | NepicastatPhase 1 · Ulcerative ColitisWeak signal | None on record | — | $91MMar 2026 | ~5.6 qtrs | $49M |
BeBetter Med688759 · SSE STAR Market | 4 assets: 2 Ph 3, 2 Ph 2 | IfupinostatPhase 3 · Relapsed/Refractory Diffuse Large B-Cell LymphomaWeak signal | Jun 2027BEBT-109 · Phase 2 | — | $144MDec 2025 | ~6.7 qtrs | $17M |
BrightGene Bio-Medical Technology688166 · SSE | 2 assets: 1 Ph 3, 1 Ph 2 | BGM0504Phase 3 · ObesityPartial signal | 28 Feb 2027BGM0504 · Phase 2 | — | — | — | $83M |
CASI Pharmaceuticals, Inc.CASIF · OTC | 2 assets: 1 approved, 1 Ph 2 | CID-103Phase 2 · Immune ThrombocytopeniaWeak signal | 30 Nov 2028CID-103 · Phase 2 | —no price since 18 Aug 2026 | $5.6MDec 2025 | Ended Apr 2026 | $6.3M |
China Resources Double-Crane Pharmaceutical600062 · SSE | 1 asset: 1 Ph 3 | GemigliptinPhase 3 · Type 2 DiabetesReliable signal | None on record | — | — | — | — |
China Resources Sanjiu Medical & Pharmaceutical000999 · SZSE | 2 assets: 1 Ph 3, 1 other | BGM0504Phase 3 · ObesityPartial signal | 28 Feb 2027BGM0504 · Phase 2 | — | $666MDec 2025 | — | $241M |
Chipscreen Biosciences688321 · SSE | 4 assets: 2 Ph 3, 1 Ph 2, 1 Ph 1 | ChidamidePhase 3 · HR+/HER2- Metastatic Breast CancerReliable signal | 18 Sep 2027CS32582 · Phase 1/2 | — | — | — | — |
CSPC Pharmaceutical Group1093 · HKEX | 11 assets: 8 Ph 3, 2 Ph 2, 1 other | PrusogliptinPhase 3 · Type 2 DiabetesReliable signal | 30 Dec 2026Anbenitamab repodatecan · Phase 3 | — | $1.4BDec 2025 | — | $809M |
Gan & Lee Pharmaceuticals603087 · SSE | 4 assets: 2 Ph 3, 2 Ph 2 | BofanglutidePhase 3 · ObesityPartial signal | 2 Feb 2027GZR101 · Phase 1 | — | — | — | $90M |
Haisco Pharmaceutical Group002653 · SZSE | 8 assets: 5 Ph 3, 1 Ph 2, 2 Ph 1 | Anrikefon (HSK21542)Phase 3 · Chronic Kidney DiseaseReliable signal | 20 Dec 2026HSK47388 · Phase 2 | — | $267MMar 2026 | — | ~$173M |
Hangzhou Zhongmei Huadong Pharmaceutical000963 · SZSE | 7 assets: 5 Ph 3, 1 Ph 2, 1 Ph 1 | janagliflozinPhase 3 · Type 2 DiabetesReliable signal | 1 Dec 2026HDM1005 · Phase 1 | — | — | — | $244M |
Hansoh Pharmaceutical Group3692 · HKEX | 17 assets: 1 approved, 10 Ph 3, 3 Ph 2, 3 Ph 1 | olatorepatidePhase 3 · ObesityReliable signal | 25 Dec 2026HS-20118 · Phase 1 | — | $4.5BDec 2025 | — | $468M |
| 1 asset: 1 Ph 3 | AlbenatidePhase 3 · Type 2 DiabetesPartial signal | None on record | — | — | — | — | |
HighTide Biopharma2511 · HKEX | 1 asset: 1 Ph 3 | Berberine ursodeoxycholate (HTD1801)Phase 3 · Type 2 DiabetesReliable signal | None on record | — | — | — | — |
Hua Medicine2552 · HKEX | 2 assets: 1 Ph 3, 1 Ph 1 | DorzagliatinPhase 3 · Type 2 DiabetesPartial signal | None on record | — | $156MDec 2025 | — | $20M |
Hubei Jumpcan Pharmaceutical600566 · SSE | 1 asset: 1 Ph 3 | EbronucimabPhase 3 · Atherosclerotic Cardiovascular DiseasePartial signal | None on record | — | — | — | — |
ImmuneOnco Biopharmaceuticals1541 · HKEX | 2 assets: 2 Ph 2 | Palverafusp alfaPhase 2 · Non-Small Cell Lung Cancer | 20 May 2027IMC-003 · Phase 1 | — | — | — | ~$46M |
Innovent Biologics1801 · HKEX | 18 assets: 4 approved, 9 Ph 3, 3 Ph 2, 2 Ph 1 | IBI305Phase 3 · Non-Small Cell Lung CancerReliable signal | 30 Nov 2026IBI363 · Phase 2 | — | $2.6BDec 2025 | 10+ years | $387M |
InventisBio688382 · SSE STAR Market | 4 assets: 4 Ph 3 | BefotertinibPhase 3 · Non-Small Cell Lung CancerPartial signal | 21 Nov 2026Nomelcitinib (D-2570) · Phase 1 | — | $173MJun 2026 | ~17.3 qtrs | ~$54M |
Jiangsu Hengrui Pharmaceuticals600276 · SSE | 116 assets: 45 Ph 3, 38 Ph 2, 26 Ph 1, 7 other | ApatinibPhase 3 · Non-Small Cell Lung CancerReliable signal | Nov 2026HRS-1780 · Phase 2 | — | $5.9BMar 2026 | — | ~$1.7B |
Jiangsu Nhwa Pharmaceutical Co., Ltd.002262 · SZSE | 2 assets: 1 Ph 2, 1 Ph 1 | NH102Phase 2 · Major Depressive DisorderPartial signal | None on record | — | $207MMar 2026 | — | $92M |
Keymed Biosciences2162 · HKEX | 6 assets: 4 Ph 3, 1 Ph 2, 1 Ph 1 | stapokibartPhase 3 · Atopic DermatitisReliable signal | Dec 2026Gamgertamig (CM336) · Phase 1/2 | — | $280MDec 2025 | ~3.8 qtrs | $100M |
Laekna Limited2105 · HKEX | 3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1 | AfuresertibPhase 3 · HR+/HER2- Metastatic Breast CancerPartial signal | 30 Jun 2027LAE102 · Phase 1 | — | $165MJun 2026 | 10+ years | ~$28M |
Luye Pharma Group2186 · HKEX | 12 assets: 4 approved, 4 Ph 3, 2 Ph 2, 2 Ph 1 | Ansofaxine hydrochloridePhase 3 · Major Depressive DisorderReliable signal | 28 Feb 2027Ansofaxine hydrochloride · Approved | — | — | — | $260M |
PegBio2565 · HKEX | 3 assets: 2 Ph 3, 1 Ph 2 | Visepegenatide (PB-119)Phase 3 · Type 2 DiabetesReliable signal | None on record | — | — | — | — |
Qyuns Therapeutics2509 · HKEX | 1 asset: 1 Ph 3 | HS-20137Phase 3 · Psoriasis | 1 Mar 2027HS-20137 · Phase 2 | — | — | — | — |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.600196 · SSE | 2 assets: 2 Ph 3 | AR1001Phase 3 · Alzheimer's DiseasePartial signal | 12 May 2027Velinotamig (GR1803) · Phase 2 | — | — | — | — |
Shanghai Pharmaceuticals Holding2607 · SSE | 2 assets: 1 Ph 3, 1 Ph 2 | SPH4336Phase 2/3 · HR+/HER2- Metastatic Breast Cancer | 1 Dec 2026SPH4336 · Phase 2/3 | — | $4.8BDec 2025 | — | $345M |
Shenzhen Salubris Pharmaceuticals002294 · SZSE | 7 assets: 3 Ph 3, 4 Ph 2 | EnarodustatPhase 3 · Chronic Kidney DiseaseReliable signal | 12 Dec 2026SAL0137 · Phase 2 | — | $157MMar 2026 | — | $79M |
Sihuan Pharmaceutical Holdings0460 · HKEX | 1 asset: 1 Ph 3 | janagliflozinPhase 3 · Type 2 DiabetesReliable signal | 31 Dec 2027janagliflozin · Approved | — | $509MDec 2025 | — | $41M |
Sino Biopharmaceutical1177 · HKEX | 16 assets: 1 approved, 7 Ph 3, 4 Ph 2, 4 Ph 1 | CulmerciclibPhase 3 · HR+/HER2- Metastatic Breast CancerPartial signal | Dec 2026Culmerciclib · Phase 3 | — | $1.8BDec 2025 | — | $866M |
Sunshine Lake PharmaPrivate | 5 assets: 2 Ph 3, 3 Ph 1 | Clifutinib BesylatePhase 3 · Acute Myeloid Leukemia | 11 Apr 2027HECN30227 · Phase 1 | — | — | — | — |
Tasly Pharmaceutical Group600535 · SSE | 6 assets: 2 Ph 3, 4 Ph 2 | QiShenYiQiPhase 3 · Heart FailurePartial signal | 31 Dec 2026Jia Shen Tablet · Phase 2 | — | — | — | $118M |
Tonghua Dongbao Pharmaceutical600867 · SSE | 2 assets: 1 Ph 3, 1 Ph 2 | THDB0206Phase 3 · Type 2 DiabetesPartial signal | None on record | — | $205MDec 2025 | — | — |
VISEN Pharmaceuticals2561 · HKEX | 2 assets: 2 approved | Approved assets only | Aug 2027palopegteriparatide · Phase 3 | — | — | — | — |
Zai LabZLAB · Nasdaq | 7 assets: 6 approved, 1 Ph 1 | ZL-1503Phase 1 · Atopic Dermatitis | 24 Nov 2026Xanomeline/trospium chloride · Phase 3 | — | $560MSep 2026 | ~10.7 qtrs | $239M |
| 1 asset: 1 Ph 2 | AC-101Phase 2 · Ulcerative Colitis | None on record | — | — | — | — | |
AffaMed TherapeuticsPrivate | 2 assets: 1 approved, 1 Ph 3 | fasedienolPhase 3 · Social Anxiety DisorderPartial signal | None on record | — | — | — | — |
Allorion TherapeuticsPrivate | 1 asset: 1 Ph 2 | AVZO-021Phase 1/2 · HR+/HER2- Metastatic Breast Cancer | 31 Jan 2028AVZO-021 · Phase 1/2 | — | — | — | — |
| 1 asset: 1 Ph 3 | ZorifertinibPhase 2/3 · Non-Small Cell Lung CancerPartial signal | 23 Apr 2028Zorifertinib · Phase 1 | — | — | — | — | |
| 1 asset: 1 Ph 1 | Anhui HygeianCells EE001Phase 1 · Heart FailureWeak signal | None on record | — | — | — | — | |
| 2 assets: 2 Ph 1 | NK520Phase 1 · Acute Myeloid LeukemiaWeak signal | Jun 2027NK510 · Phase 1 | — | — | — | — | |
| 1 asset: 1 Ph 2 | BioTTT001Phase 1/2 · Non-Small Cell Lung Cancer | 31 Jul 2027BioTTT001 · Phase 1/2 | — | — | — | — | |
Beijing Dongfang BiotechPrivate | 1 asset: 1 Ph 3 | exendin-4 Fc fusion (JY09)Phase 3 · Type 2 Diabetes | None on record | — | — | — | — |
Beijing Joekai BiotechnologyPrivate | 1 asset: 1 Ph 2 | 50561Phase 2 · Alzheimer's DiseasePartial signal | None on record | — | — | — | — |
Beijing QL BiopharmaceuticalPrivate | 3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1 | zovaglutidePhase 3 · ObesityReliable signal | 3 Dec 2026zovaglutide · Phase 1 | — | — | — | — |
| 1 asset: 1 Ph 1 | mulberry twig alkaloidsPhase 1 · ObesityWeak signal | None on record | — | — | — | — | |
| 1 asset: 1 Ph 3 | LecankitugPhase 3 · Psoriasis | None on record | — | — | — | — | |
Benethera BiotechnologyPrivate | 1 asset: 1 Ph 1 | BDHK-2009Phase 1 · Ulcerative Colitis | None on record | — | — | — | — |
Biotroy TherapeuticsPrivate | 1 asset: 1 Ph 2 | BT02Phase 1/2 · Non-Small Cell Lung Cancer | Mar 2027BT02 · Phase 1 | — | — | — | — |
| 1 asset: 1 Ph 1 | SENTI-301APhase 1 · Hepatocellular Carcinoma | None on record | — | — | — | — | |
| 1 asset: 1 Ph 3 | DA-302168SPhase 3 · ObesityPartial signal | 12 Dec 2026DA-302168S · Phase 1 | — | — | — | — | |
| 1 asset: 1 Ph 3 | YogliptinPhase 3 · Type 2 DiabetesPartial signal | None on record | — | — | — | — | |
| 2 assets: 1 Ph 3, 1 Ph 2 | Purinostat MesylatePhase 3 · Diffuse Large B-Cell Lymphoma | 15 Dec 2026Purinostat Mesylate · Phase 1 | — | — | — | — | |
| 3 assets: 1 approved, 1 Ph 3, 1 Ph 2 | LanifibranorPhase 3 · MASH / NASHPartial signal | None on record | — | — | — | — | |
| 1 asset: 1 Ph 1 | KRAS-specific Autologous TCR-T cellPhase 1 · Non-Small Cell Lung Cancer | 30 Nov 2028KRAS-specific Autologous TCR-T cell · Phase 1 | — | — | — | — | |
| 4 assets: 4 Ph 3 | stapokibartPhase 3 · Atopic DermatitisReliable signal | 25 Dec 2026Docetaxel (HB1801) · Phase 2 | — | — | — | — | |
| 1 asset: 1 Ph 2 | CTS2190Phase 1/2 · Non-Small Cell Lung Cancer | None on record | — | — | — | — | |
| 1 asset: 1 Ph 2 | HEC88473Phase 2 · Type 2 DiabetesWeak signal | None on record | — | — | — | — | |
| 1 asset: 1 Ph 3 | OrdastobartPhase 2/3 · Head and Neck Squamous Cell Carcinoma | 28 Feb 2027Ordastobart · Phase 2 | — | — | — | — | |
Evopoint Biosciences Inc.Private | 1 asset: 1 Ph 2 | ASP546CPhase 1/2 · Non-Small Cell Lung Cancer | 30 Dec 2026ASP546C · Phase 1/2 | — | — | — | — |
| 1 asset: 1 Ph 1 | INN805Phase 1 · Non-Small Cell Lung Cancer | Dec 2026INN805 · Phase 1 | — | — | — | — | |
Fosun Wanbang Pharma GroupPrivate | 1 asset: 1 Ph 3 | RoconkibartPhase 3 · PsoriasisReliable signal | None on record | — | — | — | — |
Grit BiotechnologyPrivate | 1 asset: 1 Ph 1 | GT737Phase 1 · Acute Myeloid Leukemia | Jun 2030GT737 · Phase 1 | — | — | — | — |
Guangdong Raynovent BiotechPrivate | 1 asset: 1 Ph 3 | RAY1225Phase 3 · Obesity | 1 Dec 2026RAY1225 · Phase 3 | — | — | — | — |
| 1 asset: 1 Ph 1 | MN-08Phase 1 | 30 Mar 2028MN-08 · Phase 1 | — | — | — | — | |
| 1 asset: 1 Ph 1 | HPB-092Phase 1 · Acute Myeloid Leukemia | Jun 2027HPB-092 · Phase 1 | — | — | — | — | |
| 1 asset: 1 Ph 1 | WBC100Phase 1 · Acute Myeloid Leukemia | Dec 2026WBC100 · Phase 1 | — | — | — | — | |
Hebei Senlang BiotechnologyPrivate | 2 assets: 1 Ph 2, 1 other | SENL103Phase 1/2 · Multiple MyelomaWeak signal | 1 Feb 2028SENL103 · Phase 1/2 | — | — | — | — |
| 1 asset: 1 Ph 1 | TGI-5Phase 1 · Non-Small Cell Lung Cancer | 31 Oct 2027TGI-5 · Phase 1 | — | — | — | — | |
HELP TherapeuticsPrivate | 1 asset: 1 Ph 3 | HiCM-188 (allogeneic iPSC-cardiomyocytes)Phase 3 · Heart FailurePartial signal | 30 Jun 2027HiCM-188 (allogeneic iPSC-cardiomyocytes) · Phase 3 | — | — | — | — |
Huahui HealthPrivate | 2 assets: 1 Ph 3, 1 Ph 1 | Libevitug (HH-003)Phase 3 · Chronic Hepatitis Delta | Aug 2027HH160 · Phase 1 | — | — | — | — |
| 1 asset: 1 Ph 1 | IBR733Phase 1 · Acute Myeloid Leukemia | 1 Jul 2027IBR733 · Phase 1 | — | — | — | — | |
| 2 assets: 1 Ph 3, 1 Ph 1 | VCT220Phase 3 · ObesityReliable signal | 1 Jul 2027VCT220 · Phase 2 | — | — | — | — | |
| 1 asset: 1 Ph 3 | FHND9041Phase 3 · Non-Small Cell Lung Cancer | None on record | — | — | — | — | |
| 1 asset: 1 Ph 3 | TH-SC01Phase 3 · Crohn's DiseaseWeak signal | 28 Dec 2026TH-SC01 · Phase 3 | — | — | — | — | |
Jiangxi Kvvit PharmaceuticalPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
| 1 asset: 1 Ph 3 | janagliflozinPhase 3 · Type 2 DiabetesReliable signal | 31 Dec 2027janagliflozin · Approved | — | — | — | — | |
JS InnoMed HoldingsPrivate | 1 asset: 1 Ph 1 | VIC-1911Phase 1 · Non-Small Cell Lung CancerWeak signal | None on record | — | — | — | — |
| 2 assets: 1 Ph 2, 1 Ph 1 | LT-002-158Phase 2 · Atopic Dermatitis | Jan 2028LT-002-158 · Phase 2 | — | — | — | — | |
LyncBio TherapeuticsPrivate | 1 asset: 1 Ph 1 | LYNC-101Phase 1 · Ulcerative Colitis | 19 Mar 2027LYNC-101 · Phase 1 | — | — | — | — |
| 2 assets: 2 Ph 3 | Beruzatatug pelitecanPhase 3 · Non-Small Cell Lung Cancer | Nov 2026Beruzatatug pelitecan · Phase 2 | — | — | — | — | |
MindRank AIPrivate | 1 asset: 1 Ph 3 | MDR-001Phase 3 · Obesity | Jun 2027MDR-001 · Phase 3 | — | — | — | — |
Nanjing Immunophage BiotechPrivate | 1 asset: 1 Ph 2 | IPG11406Phase 2 · Ulcerative ColitisWeak signal | 20 Nov 2028IPG11406 · Phase 2 | — | — | — | — |
Nanjing RegeneCore BiotechPrivate | 1 asset: 1 Ph 2 | RC1416Phase 2 · Chronic Obstructive Pulmonary Disease | 25 Oct 2027RC1416 · Phase 2 | — | — | — | — |
| 1 asset: 1 Ph 2 | atamparibPhase 1/2 · Non-Small Cell Lung Cancer | 31 Jul 2028atamparib · Phase 1/2 | — | — | — | — | |
Newsoara BiopharmaPrivate | 3 assets: 1 approved, 1 Ph 3, 1 Ph 1 | Prifemilast (HPP737)Phase 3 · PsoriasisPartial signal | 1 Dec 2026HY1272 · Phase 1 | — | — | — | — |
| 1 asset: 1 Ph 3 | Olvimulogene nanivacirepvecPhase 3 · Ovarian Cancer | Dec 2026Olvimulogene nanivacirepvec · Phase 3 | — | — | — | — | |
Nicoya TherapeuticsPrivate | 1 asset: 1 approved | Approved assets only | Oct 2027Extended-release calcifediol · Phase 2 | — | — | — | — |
Nuance PharmaPrivate | 1 asset: 1 approved | Approved assets only | 1 Mar 2027ensifentrine · Phase 2 | — | — | — | — |
Pediatrix TherapeuticsPrivate | 2 assets: 1 approved, 1 Ph 2 | LepzacitinibPhase 2 · Atopic Dermatitis | Apr 2027Epinephrine · Approved | — | — | — | — |
Phrontline BiopharmaPrivate | 1 asset: 1 Ph 1 | TJ101Phase 1 · Non-Small Cell Lung Cancer | 30 Dec 2026TJ101 · Phase 1 | — | — | — | — |
| 1 asset: 1 Ph 1 | PLB-002Phase 1 · Non-Small Cell Lung Cancer | 30 Jun 2027PLB-002 · Phase 1 | — | — | — | — | |
Qilu PharmaceuticalPrivate | 22 assets: 14 Ph 3, 5 Ph 2, 3 Ph 1 | AfuresertibPhase 3 · HR+/HER2- Metastatic Breast CancerPartial signal | Nov 2026QLS1304 · Phase 1 | — | — | — | — |
| 1 asset: 1 Ph 2 | HS-IT101Phase 2 · Melanoma | None on record | — | — | — | — | |
Regend TherapeuticsPrivate | 3 assets: 1 Ph 3, 2 Ph 1 | REGEND001Phase 3 · Chronic Obstructive Pulmonary DiseasePartial signal | 15 Feb 2027REGEND007 · Phase 1 | — | — | — | — |
| 2 assets: 1 Ph 3, 1 Ph 2 | JS105Phase 3 · HR+/HER2- Metastatic Breast Cancer | 26 Feb 2027JS105 · Phase 1/2 | — | — | — | — | |
S-Evans BiosciencesPrivate | 1 asset: 1 Ph 2 | Menstrual blood-derived mesenchymal stem cells (MenSCs)Phase 1/2 | None on record | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.